Intellia Therapeutics (NTLA) surged 23% after presenting additional positive Phase 3 data for lonvo-z in hereditary angioedema (HAE).
In this update, I discuss:
The latest Phase 3 results
Why the market reacted so strongly
The potential significance for Intellia’s broader gene-editing platform
What I’m watching heading into a potential 2027 launch
Here’s what I’m seeing. Think for yourself.
Disclosure: Long NTLA. This video is for informational and educational purposes only and should not be considered investment advice.
